1 / 4

* P < 0.05, telbivudine vs lamivudine at Week 104

Telbivudin. Lamivudin. BU HBV-DNA PCR-negativ zu Woche 104 bei H BeAg-negativen Patienten. GLOBE-Studie 104 Wochen. Insgesamt vs. nach Ausgangsviruslast. *. *. *. * P < 0.05, telbivudine vs lamivudine at Week 104. BU: Telbivudin bei HBeAg-negativen Patienten. GLOBE-Studie 104 Wochen.

emily-decker
Download Presentation

* P < 0.05, telbivudine vs lamivudine at Week 104

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Telbivudin Lamivudin BU HBV-DNA PCR-negativ zu Woche 104 bei HBeAg-negativen Patienten. GLOBE-Studie 104 Wochen. Insgesamt vs. nach Ausgangsviruslast * * * * P < 0.05, telbivudine vs lamivudine at Week 104

  2. BU: Telbivudin bei HBeAg-negativen Patienten. GLOBE-Studie 104 Wochen. Baseline <7 Log10 N=91 95% Der Patienten unter Telbivudin erreichen PCR-Negativität (≤300 Kopien/ml) zu Woche 24 N=86/91 91% PCR-negativ Woche 104 N=78/86 3.5% Viraler Durchbruch Woche 104 3/86

  3. Telbivudine Lamivudine HBV-DNA PCR-negativ zu Woche 104 bei HBeAg-positiven Patienten mit GPT≥ 2 x ULN. . GLOBE-Studie 104 Wochen. Insgesamt vs. nach Ausgangsviruslast. * * * * P < 0.05, telbivudine vs lamivudine at Week 104

  4. BU: Telbivudin bei HBeAg-positiven Patienten. GLOBE-Studie 104 Wochen. Baseline <9 Log10 + GPT ≥ 2 x ULN N=80 71% der Patienten unter Telbivudin erreichen PCR-Negativität (≤300 Kopien/ml) zu Woche 24 N=57/80 90% PCR-negativ Woche 104 N=51/57 52% Serokonversion Woche 104 N=30/57 3.0% Viraler Durchbruch Woche 104 N=2/57

More Related